Cecchi F, Olivotto I, Lazzeroni E, Chiriatti G, Sachero A, Beretta L, Giagnoni E, Renosto G, Montereggi A, Baldassarre S, Castelli G, Ciaccheri M
Unità di Cardiologia, S. Luca Azienda Ospedaliera Careggi, Firenze.
G Ital Cardiol. 1997 Nov;27(11):1133-43.
Most of the information available on the clinical course and prognosis of hypertrophic cardiomyopathy (HCM) is based on data generated from international referral centres and as a result, it constitutes a potentially biased perspective of the disease process in this complex and diverse condition. A multicentric study was therefore set up with the aim of providing information on unselected patient populations with HCM.
The study group comprised 330 patients from 5 non-referral hospitals (mean age 42 +/- 16 years, M/F 226/104, 74-22%-obstructive, 299-91%-in NYHA class I-II) who were followed up regularly for 9.5 +/- 5.6 years.
The vast majority of patients (n = 272, 82%) remained asymptomatic or mildly symptomatic during the follow-up period, whereas the remaining patients (n = 58, 18%) experienced clinical deterioration or died. Of the 18 patients (5%) who died of cardiovascular causes related to hypertrophic cardiomyopathy, 14 had progressive congestive heart failure and only 4 died suddenly. The annual mortality rate for cardiovascular disease was 0.57%, while the mortality rate due to sudden cardiac death was only 0.1%. The cumulative survival rate was 98, 95 and 93%, at 5, 10 and 15 years of follow-up respectively. Atrial fibrillation proved to be a relatively common (n = 81, 24%) and particularly unfavourable clinical feature, with higher mortality rate for cardiovascular causes related to hypertrophic cardiomyopathy. Syncope occurred in 47 patients (14%) but did not appear to have prognostic significance.
In an unselected population, hypertrophic cardiomyopathy had a relatively benign prognosis that was inconsistent with its prior characterization as a generally progressive disorder, based primarily on the experience of selected referral institutions. Sudden unexpected cardiac death was distinctly uncommon, although a sizable proportion of patients, particularly the subset prone to atrial fibrillation, did experience clinical deterioration.
目前关于肥厚型心肌病(HCM)临床病程和预后的大多数信息是基于国际转诊中心产生的数据,因此,对于这种复杂多样疾病的病程,这些信息构成了一个潜在有偏差的观点。因此开展了一项多中心研究,旨在提供关于未经选择的肥厚型心肌病患者群体的信息。
研究组包括来自5家非转诊医院的330例患者(平均年龄42±16岁,男/女226/104,74例[22%]为梗阻性,299例[91%]纽约心脏协会心功能分级为I-II级),对其进行了9.5±5.6年的定期随访。
在随访期间,绝大多数患者(n = 272,82%)仍无症状或症状轻微,而其余患者(n = 58,18%)出现临床病情恶化或死亡。在18例(5%)死于与肥厚型心肌病相关的心血管原因的患者中,14例有进行性充血性心力衰竭,仅4例猝死。心血管疾病的年死亡率为0.57%,而心源性猝死的死亡率仅为0.1%。随访5年、10年和15年时的累积生存率分别为98%、95%和93%。房颤被证明是一种相对常见(n = 81,24%)且特别不利的临床特征,与肥厚型心肌病相关的心血管原因导致的死亡率更高。47例患者(14%)发生晕厥,但似乎没有预后意义。
在未经选择的人群中,肥厚型心肌病的预后相对良好,这与其先前主要基于选定转诊机构的经验而被描述为一种通常进行性疾病的特征不一致。意外心源性猝死明显少见,尽管相当一部分患者,尤其是易患房颤的亚组,确实出现了临床病情恶化。